Breaking News Instant updates and real-time market news.

BFRA

Biofrontera

$12.29

(0.00%)

, EXAS

Exact Sciences

$77.78

1.65 (2.17%)

04:55
01/10/19
01/10
04:55
01/10/19
04:55

Benchmark to hold meetings during a conference

Company Meetings to be held at the JPMorgan Healthcare Conference in San Francisco on January 7-10.

BFRA

Biofrontera

$12.29

(0.00%)

EXAS

Exact Sciences

$77.78

1.65 (2.17%)

HBIO

Harvard Bioscience

$3.38

0.03 (0.90%)

STAA

STAAR Surgical

$32.58

0.46 (1.43%)

NEO

NeoGenomics

$14.96

1.83 (13.94%)

VNRX

VolitionRx

$2.38

0.095 (4.16%)

CEMI

Chembio Diagnostics

$6.55

0.05 (0.77%)

FLXN

Flexion

$13.04

-0.26 (-1.95%)

OCX

OncoCyte

$1.75

-0.13 (-6.91%)

NVTA

Invitae

$14.12

1.045 (7.99%)

  • 10

    Jan

  • 15

    Jan

  • 16

    Jan

  • 24

    Jan

  • 30

    Jan

  • 18

    May

BFRA Biofrontera
$12.29

(0.00%)

01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
11/28/18
LSCM
11/28/18
INITIATION
Target $19
LSCM
Buy
Biofrontera assumed with a Buy at Lake Street
Lake Street analyst Thomas Flaten assumed coverage of Biofrontera with a Buy rating and $19 price target. All the pieces are coming together for Biofrontera and Ameluz, its photodynamic drug therapy for pre-cancerous and cancerous skin lesions, Flaten tells investors in a research note. He believes Ameluz's "superior" clinical profile will combine with a "compelling" reimbursement story in the U.S. and a "robust" clinical development strategy to drive sales growth.
06/21/18
BNCH
06/21/18
INITIATION
Target $20
BNCH
Buy
Biofrontera assumed with a Buy at Benchmark
Benchmark analyst Bruce Jackson assumed coverage of Biofrontera AG with a Buy rating and $20 price target.
12/28/18
LSCM
12/28/18
NO CHANGE
Target $19
LSCM
Buy
Lake Street does not see court ruling hurting Biofrontera's results
Lake Street analyst Thomas Flaten affirms a Buy rating on Biofrontera with a $19 price target after Dusa Pharmaceuticals announced Wednesday that the U.S. District Court for the District of Massachusetts issued a preliminary injunction prohibiting Biofrontera from using Dusa's trade secrets in its commercial activities. Dusa sells Levulan, which competes directly with Biofrontera's Ameluz in the United States, Flaten tells investors in a research note. The analyst does not anticipate the ruling will have any material negative impact on Biofrontera's ongoing business or financial results. However, Biofrontera and Dusa are engaged in multiple lawsuits which collectively create uncertainty around Biofrontera shares, adds Flaten.
EXAS Exact Sciences
$77.78

1.65 (2.17%)

01/04/19
ADAM
01/04/19
NO CHANGE
ADAM
Illumina, Exact Science among top Diagnostics picks for 2019 at Canaccord
Canaccord analyst Mark Massaro introduced his top picks for 2019 in the Diagnostics and Tools space as he expects new tests will generate clinical and economic utility to patients and payors, which will pace positive returns in 2019. His top picks include Illumina (ILMN) with a $375 price target, Exact Sciences (EXAS) with an $87 price target, Heska (HSKA) with a $123 target, Natera (NTRA) with a $25 target, OraSure (OSUR) with an $18 target and Quidel (QDEL) with a $70 price target.
10/31/18
JEFF
10/31/18
NO CHANGE
Target $84
JEFF
Buy
Exact Sciences price target raised to $84 from $74 at Jefferies
Jefferies analyst Brandon Couillard raised his price target for Exact Sciences to $84 saying the company "bounced back" in Q3 with a "strong" beat and raise. The quarter signaled that recent operational issues are behind the company and that its momentum is rebounding, Couillard tells investors in a post-earnings research note. He maintains a Buy rating on Exact Sciences.
01/07/19
ADAM
01/07/19
NO CHANGE
Target $87
ADAM
Buy
Exact Sciences reiterated as top pick at Canaccord after 'solid' Q4 results
Canaccord analyst Mark Massaro noted Exact Sciences delivered upside to Q4 Street estimates, "easily" beating on the top-line. Its volume growth was its largest sequential quarterly growth in six quarters and its roughly 15,000 new ordering providers was the largest quarterly addition of ordering clinicians in the company's history, said Massaro, who reiterated his Buy rating and $87 price target on Exact Sciences shares.
11/29/18
UBSW
11/29/18
NO CHANGE
Target $100
UBSW
Buy
Exact Sciences doctor feedback points to upside ahead, says UBS
UBS analyst Daniel Brennan said feedback from doctors on ordering Exact Sciences' Cologuard for patients points to an increasing frequency of ordering. Brennan views this as positive and reiterated his Buy rating and $100 price target on Exact Sciences shares.
HBIO Harvard Bioscience
$3.38

0.03 (0.90%)

06/28/18
BNCH
06/28/18
INITIATION
Target $11
BNCH
Buy
Harvard Bioscience assumed with a Buy at Benchmark
Benchmark analyst Bruce Jackson assumed coverage of Harvard Bioscience with a Buy rating and $11 price target, arguing that the benefits of its transformation into a pure-play research instrumentation company via its recently completed acquisition of DSI and divestiture of Denville are still underappreciated.
01/24/18
JANY
01/24/18
NO CHANGE
Target $8
JANY
Buy
Harvard Bioscience price target raised to $8 from $5 at Janney Capital
Janney Capital analyst Paul Knight said Harvard Bioscience has become a preclinical and early stage research pure play by selling its Denville Scienctific labware distribution business and acquiring Data Sciences International. Given these changes, the company should be more closely linked to the robust growth in clinical trial activity, said Knight, who raised his fair value estimate on Harvard Bioscience to $8 from $5. He keeps a Buy rating on the stock.
04/16/18
BNCH
04/16/18
NO CHANGE
Target $10
BNCH
Buy
Benchmark says meetings reinforce positive view on Harvard Bioscience
After hosting investor meetings with Harvard Bioscience's senior management, Benchmark analyst Raymond Myers said he sees visibility to management's guidance of 55% gross margin in Q1 and he expects sharply improved results beginning with the quarter. Myers maintains a Buy rating and $10 price target on Harvard Bioscience shares.
STAA STAAR Surgical
$32.58

0.46 (1.43%)

09/14/18
ADAM
09/14/18
NO CHANGE
Target $55
ADAM
Buy
STAAR Surgical price target raised to $55 from $43 at Canaccord
Canaccord analyst Jason Mills raised his price target to $55 from $43 following the FDA approval of its Toric ICL. The analyst said it represent tangible progress for the company along the path of tapping into the U.S. refractive market and could also serve as upside to current guidance. Mills reiterated his Buy rating on STAAR Surgical shares.
08/06/18
BNCH
08/06/18
INITIATION
Target $45
BNCH
Buy
STAAR Surgical transitioned with a Buy at Benchmark
Benchmark transitioned coverage of STAAR Surgical to analyst Bruce Jackson, who sees the company having achieved a major milestone this quarter with full resolution of the FDA Warning Letter, clearing the way for the possible approval and launch of the Toric ICL later this year. Jackson has a Buy rating and $45 price target on STAAR Surgical shares.
08/02/18
ADAM
08/02/18
NO CHANGE
Target $43
ADAM
Buy
STAAR Surgical price target raised to $43 from $32 at Canaccord
Canaccord analyst Jason Mills raised his price target on STAAR Surgical to $43 from $32 following its Q2 results. The analyst said its key franchise ICL accelerated further in Q2, demonstrating the paradigm in refractive vision correction is changing in STAAR's favor. He noted the guidance was raised and he sees momentum continuing. Mills reiterated his Buy rating on STAAR Surgical shares.
09/24/18
BNCH
09/24/18
NO CHANGE
Target $54
BNCH
Buy
STAAR Surgical price target raised to $54 from $45 at Benchmark
Benchmark analyst Bruce Jackson raised his 2018 revenue estimate for STAAR Surgical to $119.2M from $118.1M, stating that the earlier than expected FDA approval of the Visian toric ICL could speed up approval of the ported version of the Visian, which he contends bodes well for 2019. The analyst, who added that the EDOF version of EVO for presbyopia could be "a game-changer," raised his price target on STAAR shares to $54 and keeps a Buy rating on the stock.
NEO NeoGenomics
$14.96

1.83 (13.94%)

01/02/19
SPHN
01/02/19
NO CHANGE
SPHN
CBS, Global Payments, Union Pacific among Stephens' best ideas for 2019
Stephens released its Best Ideas list for 2019, noting that over the last 13 years its Best Ideas list has outperformed the Russell 2000 by an average of 300 bps. Of note, six of the firm's 30 analysts listed "cash" as their best idea for this year. Among the rest, the picks included: Landstar System (LSTR), Enova (ENVA), RealPage (RP), FMC Corporation (FMC), Avanos (AVNS), Knight-Swift (KNX), CBS (CBS), Vulcan Materials (VMC), Encompass Health (EHC), Watsco (WSO), Global Payments (GPN), O'Reilly Automotive (ORLY), NeoGenomics (NEO), Continental Resources (CLR), Union Pacific (UNP), Ametek (AME), Wintrust Financial (WTFC), Helmerich & Payne (HP), Penske Automotive (PAG), Signature Bank (SBNY), Noble Energy (NBL), Origin Bancorp (OBNK), GrubHub (GRUB) and CenterState Bank (CSFL).
11/01/18
BNCH
11/01/18
NO CHANGE
Target $22
BNCH
Buy
NeoGenomics price target raised to $22 from $16 at Benchmark
Benchmark analyst Bruce Jackson noted that NeoGenomics reported earnings and revenue that beat his estimates and the company raised its revenue and adjusted EPS expectations. After raising both his estimates for 2018 and 2019 and raising the multiple he applies, Jackson lifted his price target on NeoGenomics shares to $22 and keeps a Buy rating on the stock.
01/03/19
NEED
01/03/19
INITIATION
Target $14
NEED
Buy
NeoGenomics initiated with a Buy at Needham
Needham analyst Stephen Unger started NeoGenomics with a Buy rating and $14 price target.
VNRX VolitionRx
$2.38

0.095 (4.16%)

01/17/18
BARD
01/17/18
NO CHANGE
BARD
Exact Sciences selloff overdone after ASCO abstract, says Baird
Baird analyst Catherine Ramsey attributes the sharp selloff in Exact Sciences (EXAS) shares to news of an ASCO abstract on a liquid biopsy test for colorectal cancer screening. However, based on some seemingly large issues with this study's design, she argues that the selloff is overdone. Several companies are working on blood-based CRC screening tests, with VolitionRx (VNRX) at least one that is planning near-term interim data releases, but Ramsey still believes a potential U.S. blood test is many years away, she tells investors.
05/16/18
MAXM
05/16/18
INITIATION
Target $6
MAXM
Buy
VolitionRx initiated with a Buy at Maxim
Maxim started VolitionRx with a Buy rating and $6 price target.
05/23/18
OPCO
05/23/18
INITIATION
Target $7
OPCO
Outperform
VolitionRx initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach started VolitionRx with an Outperform rating and $7 price target. The company is closing in on a blood-based diagnostic for colorectal cancer that could help address "critical gaps" in screening compliance, Breidenbach tells investors in a research note. He believes VolitionRx's Nu.Q platform has generated "compelling" early data in colorectal cancer.
07/12/18
BNCH
07/12/18
INITIATION
Target $5
BNCH
Buy
VolitionRx assumed with a Speculative Buy at Benchmark
Benchmark analyst Bruce Jackson assumed coverage of VolitionRx with a Speculative Buy rating and $5 price target, noting that the company is seeking to launch two products in 2019 - a confirmatory test for colorectal cancer to verify the results of a screening FIT test and a primary screening version of the test that uses more biomarkers.
CEMI Chembio Diagnostics
$6.55

0.05 (0.77%)

12/19/18
DOTC
12/19/18
INITIATION
Target $12
DOTC
Buy
Chembio Diagnostics initiated with a Buy at Dougherty
Dougherty analyst Kyle Bauser initiated Chembio Diagnostics with a Buy and $12 price target.
01/04/19
ADAM
01/04/19
INITIATION
Target $9
ADAM
Buy
Chembio Diagnostics initiated with a Buy at Canaccord
Canaccord analyst Mark Massaro initiated Chembio Diagnostics with a Buy rating as he believes it is an underappreciated player in the very attractive point-of-care diagnostics space. The analyst said Chembio has best-in-class test accuracy and he likes its third party partnerships model. He also believes it can increase U.S. market share and make an even greater impact outside of the United States. Massaro has a $9 price target on Chembio Diagnostics shares.
07/11/18
BNCH
07/11/18
INITIATION
Target $14
BNCH
Buy
Chembio Diagnostics assumed with a Buy from a Speculative Buy at Benchmark
Benchmark analyst Bruce Jackson assumed coverage of Chembio Diagnostics with a Buy rating and $14 price target, stating that he sees the company benefitting from several incremental growth opportunities and that its new product pipeline is "well-stocked." The stock was previously covered by Raymond Myers, who'd had a Speculative Buy rating on Chembio.
FLXN Flexion
$13.04

-0.26 (-1.95%)

01/04/19
BNCH
01/04/19
DOWNGRADE
BNCH
Hold
Flexion downgraded to Hold from Buy at Benchmark
01/04/19
BNCH
01/04/19
DOWNGRADE
BNCH
Hold
Flexion downgraded to Hold at Benchmark on limited visibility into revenue ramp
As previously reported, Benchmark analyst Bruce Jackson downgraded Flexion to Hold from Buy following last night's pre-announcement of Q4 results and issuance of lower than expected 2019 revenue guidance. While he continue to see Zilretta eventually becoming the standard of care for the treatment of osteoarthritis knee pain, Jackson recommends moving to the sidelines to "wait out the uncertainty" he sees in the near-term.
01/04/19
NEED
01/04/19
NO CHANGE
Target $36
NEED
Buy
Flexion price target lowered to $36 from $42 at Needham
Needham analyst Serge Belanger lowered his price target on Flexion to $36 after its yesterday's guidance for FY19 Zilretta sales of $65M-$80M came in below the Street consensus of $97.8M. The analyst states that although the outlook may appear disappointing at first, investors may welcome the "expectation reset" that should yield a "more accurate guidepost" for Zilretta growth. The analyst also lowered his FY19 EPS view to ($3.89) from ($2.63) to reflect the slower launch ramp but kept his Buy rating on the shares based on the company's potential for its product to serve as the front-line treatment for Osteoarthritis knee pain.
01/04/19
BMOC
01/04/19
NO CHANGE
Target $34
BMOC
Outperform
Flexion price target lowered to $34 from $36 at BMO Capital
BMO Capital analyst Gary Nachman lowered his price target on Flexion to $34 after the company's FY19 outlook for Zilretta sales disclosed yesterday. The analyst states that the management has deliberately set an "appropriately conservative" target, adding that Zilretta momentum should accelerate "with the J-code in place effective January 1st". Nachman also believes that the set-up on the stock has "improved meaningfully".
OCX OncoCyte
$1.75

-0.13 (-6.91%)

07/11/18
07/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alphabet (GOOGL, GOOG), Facebook (FB), and Spotify (SPOT) were initiated with a Buy at Nomura Instinet while Twitter (TWTR) was initiated with a Reduce. 2. AMC Entertainment (AMC) and Cinemark (CNK) were initiated with an Outperform at Imperial Capital. 3. Keurig Dr Pepper (KDP) initiated with a Hold at Stifel. 4. Myers Industries (MYE) initiated with a Neutral at Baird and JPMorgan. 5. TPG Pace Energy (TPGE) initiated with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/18
JANY
09/10/18
NO CHANGE
Target $4
JANY
Buy
OncoCyte price target raised to $4 from $2 at Janney Montgomery Scott
12/19/18
LSCM
12/19/18
INITIATION
Target $4
LSCM
Buy
OncoCyte assumed with a Buy at Lake Street
Lake Street analyst Thomas Flaten assumed coverage of OncoCyte with a Buy rating and $4 price target. The company's DetermaVu is a non-invasive confirmatory diagnostic with the potential to improve lung cancer diagnosis and care, while reducing costs to the system, Flaten tells investors in a research note.
07/11/18
BNCH
07/11/18
INITIATION
Target $7
BNCH
Buy
OncoCyte assumed with a Buy from a Speculative Buy at Benchmark
Benchmark analyst Bruce Jackson assumed coverage of OncoCyte with a Buy rating and $7 price target, stating that he sees a "clear pathway to commercial availability" for its blood-based lung cancer test, which he believes can prevent the need for risky and expensive lung tissue biopsy procedures. The stock was previously covered by Raymond Myers, who'd had a Speculative Buy rating on OncoCyte.
NVTA Invitae
$14.12

1.045 (7.99%)

11/08/18
JPMS
11/08/18
NO CHANGE
Target $16
JPMS
Overweight
Invitae price target raised to $16 from $12 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Invitae to $16 saying the company posted another "solid beat and raise" quarter. The analyst maintains an Overweight rating on the shares.
11/20/18
BNCH
11/20/18
INITIATION
Target $17
BNCH
Buy
Invitae assumed with a Buy at Benchmark
Benchmark analyst Bruce Jackson assumed coverage of Invitae with a Buy rating and $17 price target. The analyst sees the company's growth in 2019 being driven by expansion into the obstetrics/gynecology market, supported by non-invasive prenatal testing and expanded carrier screening. Invitae aims to be the market leader in genetic testing, says the analyst.
11/20/18
11/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hexcel (HXL) initiated with a Neutral at Longbow. 2. CatchMark Timber (CTT) initiated with a Neutral at Citi. 3. Brookfield Business Partners (BBU) initiated with an Outperform at BMO Capital. 4. Invitae (NVTA) assumed with a Buy at Benchmark. 5. Molecular Templates (MTEM) initiated with an Outperform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/18
OPCO
12/19/18
INITIATION
Target $20
OPCO
Outperform
Invitae initiated with an Outperform at Oppenheimer
Oppenheimer analyst Kevin DeGeeter started Invitae with an Outperform rating and $20 price target. The analyst views Invitae as benefiting from several trends driving growth for the genetic testing sector, including declining cost of goods and price for genetic testing, growing consumer demand for genetic information at key healthcare inflection point, and growing power of consumer brand as a tool to capture share of the rapidly growing cash-pay segment. Further, DeGeeter believes Invitae is the only company truly positioned to benefit from these trends due to management's focus on competing on cost of goods and price, expanding breadth of test menu and access to capital to fund DTC advertising.

TODAY'S FREE FLY STORIES

INTC

Intel

$57.52

-1.2 (-2.04%)

15:40
04/25/19
04/25
15:40
04/25/19
15:40
Options
Intel options volume is 2X daily average ahead of earnings »

Intel options volume is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 16

    May

  • 03

    Jun

S

Sprint

$5.54

-0.08 (-1.42%)

, TMUS

T-Mobile

$73.06

-0.29 (-0.40%)

15:38
04/25/19
04/25
15:38
04/25/19
15:38
Periodicals
Sprint, T-Mobile officials 'cautiously optimistic' about DOJ approval, FBN says »

The U.S. Department of…

S

Sprint

$5.54

-0.08 (-1.42%)

TMUS

T-Mobile

$73.06

-0.29 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

SFLY

Shutterfly

$42.23

-0.72 (-1.68%)

15:34
04/25/19
04/25
15:34
04/25/19
15:34
Options
Shutterfly options imply 13.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

XLU

Utilities SPDR

$58.16

0.38 (0.66%)

15:30
04/25/19
04/25
15:30
04/25/19
15:30
Options
Put spreads in SPDR Utility Fund as a defensive position is adjusted »

Put spreads in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$20.19

-0.565 (-2.72%)

15:29
04/25/19
04/25
15:29
04/25/19
15:29
Hot Stocks
EQT Corporation responds to Toby Rice lawsuit »

EQT Corporation issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NBLX

Noble Midstream

$36.79

-0.64 (-1.71%)

, NBL

Noble Energy

$26.70

-0.89 (-3.23%)

15:22
04/25/19
04/25
15:22
04/25/19
15:22
Periodicals
Breaking Periodicals news story on Noble Midstream, Noble Energy »

Noble Midstream put up…

NBLX

Noble Midstream

$36.79

-0.64 (-1.71%)

NBL

Noble Energy

$26.70

-0.89 (-3.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

GM

General Motors

$39.16

-0.57 (-1.43%)

15:20
04/25/19
04/25
15:20
04/25/19
15:20
Hot Stocks
GM adds second shift, over 400 hourly jobs to Kentucky assembly plant »

General Motors said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 05

    Jun

ALKS

Alkermes

$31.49

-3.31 (-9.51%)

15:20
04/25/19
04/25
15:20
04/25/19
15:20
Recommendations
Alkermes analyst commentary at Piper Jaffray »

Piper points to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ZNGA

Zynga

$5.46

-0.125 (-2.24%)

15:20
04/25/19
04/25
15:20
04/25/19
15:20
Options
Size call spread in Zynga adjusts a bullish position »

Size call spread in Zynga…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 07

    May

  • 13

    Nov

JNPR

Juniper

$28.11

-0.615 (-2.14%)

15:19
04/25/19
04/25
15:19
04/25/19
15:19
Options
Juniper options imply 10.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
04/25/19
04/25
15:17
04/25/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
04/25/19
04/25
15:16
04/25/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADM

Archer Daniels

$42.08

-0.68 (-1.59%)

15:15
04/25/19
04/25
15:15
04/25/19
15:15
Options
Archer Daniels put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 01

    May

  • 13

    Nov

CLS

Celestica

$7.33

-1.275 (-14.82%)

15:06
04/25/19
04/25
15:06
04/25/19
15:06
Downgrade
Celestica rating change at CIBC »

Celestica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MAT

Mattel

$12.39

-0.16 (-1.27%)

15:04
04/25/19
04/25
15:04
04/25/19
15:04
Options
Mattel options imply 17.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 16

    May

  • 12

    Jun

MDP

Meredith

$58.14

-0.21 (-0.36%)

15:02
04/25/19
04/25
15:02
04/25/19
15:02
Periodicals
Authentic Brands in talks to buy Sports Illustrated from Meredith, WSJ says »

Authentic Brands has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 09

    May

  • 13

    Nov

CMG

Chipotle

$676.86

-33.14 (-4.67%)

14:59
04/25/19
04/25
14:59
04/25/19
14:59
Recommendations
Chipotle analyst commentary at Argus »

Chipotle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 29

    May

MS

Morgan Stanley

$47.53

0.14 (0.30%)

14:58
04/25/19
04/25
14:58
04/25/19
14:58
Hot Stocks
California AG announces $150M settlement agreement with Morgan Stanley »

California Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 03

    Jun

  • 11

    Jun

SBUX

Starbucks

$76.81

0.39 (0.51%)

14:53
04/25/19
04/25
14:53
04/25/19
14:53
Earnings
Fly Intel: What to watch in Starbucks earnings report »

Starbucks (SBUX) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

AKAM

Akamai

$78.74

0.61 (0.78%)

14:53
04/25/19
04/25
14:53
04/25/19
14:53
Conference/Events
Akamai management to meet with William Blair »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 02

    May

  • 15

    May

  • 06

    Jun

AMZN

Amazon.com

$1,915.66

14.94 (0.79%)

14:50
04/25/19
04/25
14:50
04/25/19
14:50
On The Fly
Fly Intel: What to watch in Amazon earnings report »

Amazon (AMZN) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

AMP

Ameriprise

$145.43

1.475 (1.02%)

14:50
04/25/19
04/25
14:50
04/25/19
14:50
Recommendations
Ameriprise analyst commentary at Citi »

Ameriprise price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

GRUB

GrubHub

$70.14

0.84 (1.21%)

14:49
04/25/19
04/25
14:49
04/25/19
14:49
Options
GrubHub options imply 18.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 21

    May

  • 28

    May

  • 05

    Jun

GLNCY

Glencore

$0.00

(0.00%)

14:47
04/25/19
04/25
14:47
04/25/19
14:47
Hot Stocks
Glencore says being investigated by CFTC over 'corrupt practices' »

Glencore said it has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 02

    May

  • 03

    May

CNSL

Consolidated Communications

$6.03

-2.86 (-32.17%)

14:29
04/25/19
04/25
14:29
04/25/19
14:29
Downgrade
Consolidated Communications rating change at Raymond James »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.